Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Apogee Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 2 insiders, $4.14M in total
- Insiders trading
- 2
- Net value
- −$4.14M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Apogee Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harwin Peter Evan | Director | 0Indirect | Sep 3, 2026 | 3 |
| Fairmount Healthcare Fund II L.P. | Director | 0Indirect | Sep 3, 2026 | 3 |
| Fairmount Funds Management LLC | Director | 0Indirect | Sep 3, 2026 | 4 |
| Kiselak Tomas | Director | 0Indirect | Sep 3, 2026 | 4 |
| McKenna Mark C. | Director | 0 | Sep 3, 2026 | 2 |
| Jones William A Jr | Director | 0 | Sep 3, 2026 | 2 |
| Dambkowski Carl | Chief Medical Officer | 0 | Sep 3, 2026 | 15 |
| Fox Jennifer A. | Director | 0 | Sep 3, 2026 | 2 |
| Henderson Jane | Chief Financial Officer | 0 | Sep 3, 2026 | 14 |
| Bollinger Lisa | Director | – | Sep 3, 2026 | 2 |
| Henderson Michael Thomas | Chief Executive Officer | 0 | Sep 3, 2026 | 14 |
| Shah Nimish P | Director | 0Indirect | Sep 3, 2026 | 3 |
| Gottesdiener Andrew | Director | – | Jun 20, 2025 | 0 |
| Fairmount Healthcare Fund L.P. | Director | 2,048,647Indirect | Apr 1, 2024 | 0 |
| Fairmount Healthcare Co-Invest II L.P. | Director | 51,166Indirect | Jan 31, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2024 (view filing) | Dec 11 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −4.54K | $48.76 | −$221.4K | −1.7%258.1K after | 2 lots10b5-1 |
| Dec 6, 2024 (view filing) | Dec 4 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −6.67K | $46.07 | −$307.1K | −2.5%260.8K after | 10b5-1 |
| Dec 6, 2024 (view filing) | Dec 4 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $46.58 | −$698.7K | −1.1%1.32M after | 2 lots10b5-1 |
| Nov 8, 2024 (view filing) | Nov 6 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −6.67K | $59.12 | −$394.0K | −2.4%267.5K after | 2 lots10b5-1 |
| Nov 8, 2024 (view filing) | Nov 6 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $59.22 | −$888.3K | −1.1%1.34M after | 2 lots10b5-1 |
| Oct 4, 2024 (view filing) | Oct 2 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −6.67K | $56.26 | −$375.0K | −2.4%274.1K after | 2 lots10b5-1 |
| Oct 4, 2024 (view filing) | Oct 2 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $56.23 | −$2.25M | −2.9%1.35M after | 2 lots10b5-1 |
| Sep 6, 2024 (view filing) | Sep 4 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −6.67K | $47.56 | −$317.0K | −2.3%280.8K after | 2 lots10b5-1 |
| Sep 6, 2024 (view filing) | Sep 4 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $47.62 | −$1.90M | −2.8%1.39M after | 2 lots10b5-1 |
| Aug 23, 2024 (view filing) | Aug 23 | Same day | Henderson JaneChief Financial Officer | SSale | −6.00K | $48.26 | −$289.6K | −2.9%200.9K after | |
| Aug 9, 2024 (view filing) | Aug 7 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −7.33K | $40.67 | −$298.3K | −2.5%287.5K after | 3 lots10b5-1 |
| Aug 9, 2024 (view filing) | Aug 7 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $40.62 | −$1.62M | −2.7%1.43M after | 3 lots10b5-1 |
| Jul 5, 2024 (view filing) | Jul 5 | Same day | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $37.26 | −$558.9K | −1.0%1.47M after | 10b5-1 |
| Jul 5, 2024 (view filing) | Jul 3 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −6.00K | $37.60 | −$225.4K | −2.0%294.8K after | 2 lots10b5-1 |
| Jul 17, 2023 (view filing)8:00 PM ET | Jul 13 | 4 days | Harwin Peter Evan and 5 othersDirector | PPurchase | +2.94M | $17.00 | +$50.0M | New position892.5K after | 3 lots |
| Jul 17, 2023 (view filing) | Jul 13 | 4 days | Shah Nimish PDirector | PPurchase | +1.75M | $17.00 | +$29.8M | New position1.75M after |